Selecta Biosciences


Seite 1 von 1
Neuester Beitrag: 02.03.23 08:30
Eröffnet am:17.06.22 05:34von: Chalifmann3Anzahl Beiträge:6
Neuester Beitrag:02.03.23 08:30von: Fu HuLeser gesamt:3.334
Forum:Hot-Stocks Leser heute:7
Bewertet mit:


 

23601 Postings, 6170 Tage Chalifmann3Selecta Biosciences

 
  
    #1
17.06.22 05:34
hochinteressanter guenstiger gentherapiewert mit starken insiderkauefen un nur die besten partnerschaften

Selecta Biosciences, Inc. (SELB)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Quote Lookup

1.3400+0.1900 (+16.52%)
At close: June 16 04:00PM EDT
 

23601 Postings, 6170 Tage Chalifmann3laeuft doch

 
  
    #2
08.08.22 17:35

23601 Postings, 6170 Tage Chalifmann3hi

 
  
    #3
08.08.22 17:37
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.  

1612 Postings, 3564 Tage Fu HuMitte bis Ende Februar werden die

 
  
    #4
31.01.23 09:51
Resultate von Ph3 präsentiert. Anscheinend äußerst positiv. Fragt sich ob und wann es dann die nächsten Milestone Payments geben wird. Was jetzt schon fix ist, SELB hat ergebnistechnisch das beste Jahr seit bestehen und es könnte zum ersten mal ein Plus unten stehen.  

2309 Postings, 1839 Tage BananiCanaccord Genuity has increased the price target

 
  
    #5
02.02.23 09:13
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ: SELB) from $9 to $10 while maintaining the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-212 for chronic refractory gout.....

https://finance.yahoo.com/news/...cta-biosciences-gout-181548891.html  

1612 Postings, 3564 Tage Fu HuHeute Nachmittag entweder über 1,80€

 
  
    #6
02.03.23 08:30
oder unter 1,20€  

   Antwort einfügen - nach oben